Xospata 40mg Tablet

About

Xospata 40mg Tablet, containing gilteritinib, is a potent oral kinase inhibitor specifically designed for the treatment of acute myeloid leukemia (AML) in adult patients who have relapsed or are refractory to prior therapy and have a FLT3 mutation. This medication targets the FMS-like tyrosine kinase 3 (FLT3) receptor, which is frequently mutated in AML and contributes to uncontrolled cell proliferation and survival. By selectively inhibiting FLT3, gilteritinib disrupts the signaling pathways essential for leukemic cell growth, leading to apoptosis and differentiation of these malignant cells. Its mechanism of action is crucial in addressing a specific genetic subtype of AML, offering a targeted therapeutic approach.

The drug's efficacy is particularly noted in patients with FLT3-ITD or FLT3-TKD mutations, which are associated with a poorer prognosis in AML. Xospata works by blocking the activity of both FLT3-ITD and FLT3-TKD mutations, thereby inhibiting the proliferation of FLT3-mutated leukemic cells. This targeted therapy represents a significant advancement in the management of relapsed or refractory FLT3-mutated AML, providing a valuable option for patients with limited treatment alternatives. Regular monitoring for treatment response and potential adverse effects, including differentiation syndrome and QT prolongation, is essential throughout the course of therapy to ensure optimal patient outcomes and safety.

Uses

• Treatment of relapsed or refractory acute myeloid leukemia (AML)
• Specifically for AML with a FLT3 mutation
• Used in adult patients after prior therapy
• Part of a targeted therapy approach for specific genetic subtypes

Directions For Use

Take this tablet orally once daily, with or without food, as directed by your oncologist. Swallow the tablet whole.

Benefits

• Targets specific FLT3 mutations in AML
• Improves remission rates in relapsed/refractory AML
• Extends overall survival in specific patient populations
• Offers an oral, targeted treatment option
• Reduces leukemic cell proliferation
• Provides a crucial option for difficult-to-treat AML

Side Effects

• Diarrhea
• Nausea
• Fatigue
• Elevated liver enzymes
• Constipation
• Edema
• Dyspnea
• Muscle pain
• Headache
• QT prolongation
• Pancreatitis
• Differentiation syndrome

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate liver-related side effects and overall systemic stress during chemotherapy.
• Pregnancy - Contraindicated. This medication can cause fetal harm. Women of childbearing potential must use effective contraception.
• Breastfeeding - Contraindicated. Discontinue breastfeeding during treatment and for at least 2 months after the last dose due to potential harm to the infant.
• Liver - Use with caution in patients with hepatic impairment. Monitor liver function tests closely and adjust dose as necessary.
• Kidney - Use with caution in patients with renal impairment. Monitor renal function regularly, though specific dose adjustments are not always required.
• Lung - Monitor for signs and symptoms of interstitial lung disease or pneumonitis, which can be serious adverse reactions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.